Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients by unknown
Li et al. BMC Cancer 2014, 14:986
http://www.biomedcentral.com/1471-2407/14/986RESEARCH ARTICLE Open AccessPhase II study of weekly irinotecan and
capecitabine treatment in metastatic colorectal
cancer patients
Wenhua Li1,2, Jianming Xu3, Lin Shen4, Tianshu Liu5, Weijian Guo1,2, Wen Zhang1,2, Zhiyu Chen1,2, Xiaodong Zhu1,2
and Jin Li1,2*Abstract
Background: The purpose of this phase II study was to evaluate the safety and efficacy of weekly irinotecan and
capecitabine (wXELIRI) treatment in patients with metastatic colorectal cancer, specifically the rate of severe
diarrhea.
Methods: Patients with unresectable histologically confirmed metastatic colorectal cancer with measurable disease
received weekly irinotecan 90 mg/m2 on day 1 and capecitabine 1200 mg/m2 twice daily on days 1–5. Patients
naïve to systemic chemotherapy for metastatic disease or who had failed FOLFOX (infusional 5-fluorouracil [5-FU],
leucovorin, and oxaliplatin) or XELOX (capecitabine plus oxaliplatin) as first-line treatment were eligible. The primary
endpoint was the rate of grade 3/4 diarrhea. Secondary endpoints included progression-free survival (PFS), overall
survival (OS), and safety.
Results: A total of 52 patients were enrolled, 30 of whom received wXELIRI as first-line treatment and 22 as
second-line treatment. Grade 4 diarrhea was observed in one patient and the rate of grade 3/4 diarrhea was 7.7%.
The other common grade 3/4 toxicities included leukopenia (9.6%), neutropenia (17.3%), nausea (3.8%), vomiting
(3.8%), fatigue (1.9%), and hand-foot syndrome (1.9%). The median progression-free survival and overall survival for
the 30 patients treated in the first-line setting was 8.5 and 16.3 months, while those for the 22 patients treated in
the second-line setting was 5.0 and 10.7 months, respectively.
Conclusions: The wXELIRI regimen resulted in a low rate of severe diarrhea with an acceptable toxicity profile. This
study provides a basis for a subsequent randomized controlled study of wXELIRI versus FOLFIRI (irinotecan, 5-FU,
and folinic acid) to further explore the efficacy and safety of this regimen.
Trial registration: ClinicalTrials.gov: NCT01322152.
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Colorectal cancer, the second leading cause of cancer
death in the USA, has increased in frequency in China in
recent years. Based on a registry in Shanghai, a city with a
population of 23 million, colorectal cancer has become
the third most prevalent malignancy [1]. Approximately* Correspondence: fudanlijin@163.com
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unless otherwise stated.50-60% of patients diagnosed with colorectal cancer will
develop metastases [2,3], for whom systematic chemother-
apy is the standard treatment.
Irinotecan combined with continuous infusion of 5-
fluorouracil (5-FU) and folinic acid (the FOLFIRI regimen)
is the established option for first- and/or second-line
treatment of metastatic colorectal cancer. Capecitabine,
an oral fluoropyrimidine that mimics continuous 5-FU
infusion by generating 5-FU preferentially in the tumor
tissues [4], has been shown to have comparable efficacy
to 5-FU/folinic acid as first-line treatment of metastatic
colorectal cancer, with an additional benefit of convenientis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ation of irinotecan and capecitabine (XELIRI) has been
assessed, but the associated gastrointestinal toxicity,
especially the incidence of severe diarrhea, affected the
feasibility of this regimen [6,7]. The incidence of grade
3/4 diarrhea was higher (17-36% vs 12-15%) with a 3-week
XELIRI regimen than with the FOLFIRI regimen [8-11],
and non-superior time to progression (TTP; 6-9 months
vs 6.7-8.5 months) and overall survival (OS; 13-20 months
vs 14.8-17.4 months) were observed [12-14]. Toxicity-
induced dose reduction and treatment delay weakened
the efficacy of the XELIRI regimen.
To reduce the side effect of diarrhea, a 2-week XELIRI
regimen was tried recently. The 2-week regimen (irino-
tecan on day 1, capecitabine on days 2-8 or days 1-5 and
8-12) exhibited promising activity (TTP, 8-10 months,
OS, 15-19 months) with improved tolerability (grade 3/4
diarrhea, 8.1-15.0%) [15,16], but an increased rate of
severe diarrhea was noted in elderly patients, which
resulted in dose reduction [15].
This study aimed to evaluate the tolerability of a weekly
XELIRI regimen as first- or second-line treatment in
patients with metastatic colorectal cancer. The dose and
schedule was chosen based on the assumption that
5 days on/2 days off administration of capecitabine may
better mimic continuous 5-FU infusion [16]. The dose
of irinotecan was calculated as a weekly dose according
to the FOLFIRI regimen [14]. The study investigated the
possibility of a further reduction of the rate of severe
diarrhea with weekly XELIRI treatment, and evaluated
the safety and efficacy of this schedule in Chinese
patients with metastatic colorectal cancer.
Methods
Patients
Patients aged 18-70 years with histologically or cyto-
logically confirmed advanced colorectal adenocarcinoma,
with an Eastern Cooperative Oncology Group perform-
ance status of 0 to 1 and life expectancy of ≥ 3 months
were eligible. Patients who were chemotherapy-naive
or who had failed first-line treatment with either XELOX
or FOLFOX were enrolled if they had at least one meas-
urable disease lesion according to the Response Evaluation
Criteria in Solid Tumors (RECIST) criteria, version 1.1.
Previous (neo) adjuvant chemotherapy was permitted if
it had been completed ≥ 6 months before enrollment,
although prior irinotecan therapy was not allowed.
Patients were required to have adequate bone marrow,
hepatic, and renal function. Patients with previous
chronic inflammatory bowel disease, chronic diarrhea or
recurrent bowel obstruction, pelvic radiotherapy within
6 months, or symptomatic brain metastases were ex-
cluded. The study was approved by the independent
ethics committee of Fudan University Shanghai CancerCenter, Shanghai, China and registered at ClinicalTrials.
gov (NCT01322152). The study was carried out in
accordance with the Declaration of Helsinki. All patients
provided written informed consent before study entry.
Treatment
All enrolled patients received a weekly regimen of irino-
tecan and capecitabine (wXELIRI), as follows: irinotecan
(Campto®, Pfizer) 90 mg/m2 given intravenously on day 1;
capecitabine (Xeloda®, Roche) 1200 mg/m2 given orally
twice daily on days 1-5. The treatment cycles were
administered every week until disease progression or
unacceptable toxicity, or consent withdrawal. For pa-
tients with poor tolerance to toxicities, treatment delay
was permitted for no more than 2 weeks.
Unless contraindicated, atropine could be given to
prevent the cholinergic adverse effects (including early
diarrhea). Loperamide was recommended as the stand-
ard anti-diarrhea treatment, and other symptomatic
treatment could be given according to the institution’s
practice guidelines.
Dose modification
Dose adjustments were made based on the worst grade
of toxicity encountered during the previous cycle. For
hematological toxicities, the dose of chemotherapeutic
drugs was reduced in the following cases: grade 4 neu-
tropenia or leukopenia; grade 3 or greater febrile neu-
tropenia; grade 3 or greater thrombocytopenia. For
nonhematological toxicity, the dose of related drug was
reduced when grade 3 or greater toxicities occurred
(except for alopecia). The dose of irinotecan or cape-
citabine was reduced by 25% of the starting dose. If a
patient required more than two successive dose reduc-
tions, therapy was dicontinued.
Treatment was delayed until the absolute neutrophil
count was ≥ 1.5 × 109/L and platelet count was ≥ 80 ×
109/L, and recovery to grade ≤ 1 for mucositis, diarrhea
and other toxicities (with exception of alopecia).The
maximum authorized delay is of 2 weeks.
Assessments
Pretreatment assessment included a detailed medical
history, physical examination, routine laboratory tests,
and performance status. Laboratory evaluation included
a routine blood count, urinalysis, and electrolyte, renal,
and liver function tests. Adverse events and concomi-
tant medications were recorded at the end of each cycle.
Toxicity was evaluated and graded according to the
National Cancer Institute Common Terminology Criteria
for Adverse Events, version 4.0.
Radiographic scans (computed tomography or magnetic
resonance imaging) for efficacy evaluation were conducted
at baseline and every 2 months thereafter according to the
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reported. Survival status was assessed every 3 months
after discontinuation of study treatment.
Statistical analysis
This phase II study was designed to assess the rate of
severe diarrhea (calculated as the percentage of patients
with grade 3 and grade 4 diarrhea) with the wXELIRI
regimen. The rate of severe diarrhea with the 2-week
XELIRI or the FOLFIRI regimens was reported as 15%
[15,17], and we supposed that the rate with the wXE-
LIRI regimen was, at most, 5%. A one-stage Fleming
design, with an exact significance level of p = 0.05 and a
power of 80%, was used to test the hypothesis. With a
sample size of 52 evaluable patients, the regimen would
be declared promising if less than 6 patients with severe
diarrhea were observed.
The efficacy analysis included all patients who received
at least one dose of study medication and had at least
one efficacy evaluation after baseline. For the safety ana-
lysis, all patients who received one dose of study medica-
tion were included. The primary study end point was
the rate of severe diarrhea. Secondary end points were
PFS (defined as the time between the first dose of study
medication and first documented disease progression orTable 1 Clinical and demographic characteristics at enrollmen
Characteristic All patients
Number (%)










Positive history of diabetes 9 (17.3)




Abdominal cavity 18 (34.6)
Number of metastatic lesions
Single 24 (46.2)
Multiple 28 (53.8)
ECOG: Eastern Cooperative Oncology Group.death), ORR, DCR (defined as the percentage of patients
with CR, PR, and SD for at least 8 weeks), OS (defined
as the time between the first dose of study medication
and death), and safety.
Survival function of time-to-event end points was esti-
mated by using the Kaplan-Meier method. Chi-square
test was performed for enumeration data on response
rate and clinical benefit rate.
Results
Patients
From March 2011 to October 2012, a total of 52 pa-
tients (25 men and 27 women), aged from 26 to 70 years
(median, 60 years) with advanced colorectal cancer
received wXELIRI treatment. Previous chemotherapy
regimens for the patients receiving second-line treat-
ment included FOLFOX (infusional 5-FU, leucovorin,
and oxaliplatin) and XELOX (capecitabine plus oxali-
platin). Table 1 shows the patients’ demographic and
clinical characteristics at enrollment.
Treatment
Up to 31 April 2013, the 52 enrolled patients had received
a total of 644 cycles of wXELIRI. The median number
of treatment cycles was 12 (range, 1-50). Median doset (N = 52)
First-line treatment Second-line treatment
Number (%) Number (%)
30 (57.7) 22 (42.3)
60 (32-70) 60 (26-68)
10 (33.3) 10 (45.5)
20 (67.7) 12 (54.5)
18 (60.0) 14 (63.6)
12 (40.0) 8 (36.4)
16 (53.3) 16 (72.7)
14 (46.7) 6 (27.3)
5 (16.7) 4 (18.2)
26 (86.7) 20 (90.9)
16 (53.3) 15 (68.2)
13 (43.3) 5 (22.7)
8 (26.7) 10 (45.5)
15 (50.0) 9 (40.9)
15 (50.0) 13 (59.1)
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the planned dose) were 80.0% for irinotecan, and 78.9%
for capecitabine. Thirty treatment cycles (4.7%) were
delayed for 23 patients — 22 cycles for 15 patients
receiving wXELIRI as first-line treatment and 8 cycles
for 8 patients receiving wXELIRI as second-line treat-
ment. The drug dose was reduced in 80 cycles (12.4%)
in 7 patients — 28 cycles for 4 patients receiving wXE-
LIRI as first-line treatment and 52 cycles for 3 patients
receiving wXELIRI as second-line treatment. Leucopenia,
diarrhea, nausea, vomiting, and hand-foot syndrome
were the main causes of dose delay and reduction.
Safety
The overall incidence of grade 3/4 adverse events was
55.5%. The most common adverse events (≥20%) were
neutropenia, leucopenia, diarrhea, nausea, vomiting,
anorexia, and fatigue (Table 2). The rate of severe diarrhea,
the primary study end point, was 7.7% (6.7% and 9.0% forTable 2 Incidence of adverse reactions caused by weekly irino
Adverse reaction Grade I Gra
Number (%) Nu
Hematologic toxicity
Leukopenia 12 (23.1) 14
Neutropenia 9 (17.3) 10
Febrile neutropenia 3 (5.8) 0 (0
Thrombocytopenia 5 (9.6) 3 (5
Anemia 7 (13.5) 13
Non-hematologic toxicity
Diarrhea 16 (30.8) 5 (9
Nausea 13 (25.0) 7 (1
Vomiting 7 (13.5) 11
Anorexia 11 (21.2) 3 (5
Fatigue 11 (21.2) 8 (1
Alopecia 5 (9.6) 0 (0
Hand-foot syndrome 3 (5.8) 0 (0
Oral ulceration 5 (9.6) 1 (0
Venous thrombus 1 (1.9) 0 (0
Pulmonary infection 1 (1.9) 1 (1
Hyperbilirubinemia 2 (3.8) 0 (0
Constipation 1 (1.9) 1 (1
Elevated creatinine 1 (1.9) 0 (0
Elevated blood glucose 1 (1.9) 1 (1
Respiratory alkalosis 1 (1.9) 0 (0
Pain 3 (5.8) 0 (0
Hypophosphatemia 0 (0) 0 (0
Hypomagnesemia 0 (0) 1 (1
Hypokalemia 0 (0) 0 (0the first- and second-line settings, respectively), with one
case of grade 4 diarrhea in the second-line setting
(Table 3). Grade 3 diarrhea occurred in three patients, one
each during the first, third, and fifth treatment cycles, and
was relieved by symptomatic treatment for diarrhea and
dehydration. Subsequent re-treatment did not result in
diarrhea greater than grade 2. The incidence of grade
1/2 diarrhea was 40.4%, and the symptoms were re-
lieved after standard use of loperamide and symptom-
atic supportive treatment in most patients.
Nausea and vomiting was another frequent gastro-
intestinal reaction, with an incidence of 38.5-42.3%.
After prophylactic administration of an antiemetic drug
(5-hydroxytryptamin 3 [5-HT 3] receptor antagonists),
nausea and vomiting was tolerable in most cases. One
patient had dose reduction and delayed treatment due
to intolerable grade 3 vomiting.
The major hematological toxicities were leucopenia
and neutropenia. Three patients developed grade 4tecan and capecitabine (N = 52)
de II Grade III Grade IV
mber (%) Number (%) Number (%)
(26.9) 5 (9.6) 0 (0)
(19.2) 6 (11.5) 3 (5.8)
) 1 (1.9) 0 (0)
.8) 0 (0) 0 (0)
(25) 1 (1.9) 0 (0)
.6) 3 (5.8) 1 (1.9)
3.5) 2 (3.8) 0 (0)
(21.2) 2 (3.8) 0 (0)
.8) 0 (0) 0 (0)
5.4) 1 (1.9) 0 (0)
) 0 (0) 0 (0)
) 1 (1.9) 0 (0)
) 1 (1.9) 0 (0)
) 0 (0) 0 (0)
.9) 0 (0) 0 (0)
) 0 (0) 0 (0)
.9) 0 (0) 0 (0)
) 0 (0) 0 (0)
.9) 0 (0) 0 (0)
) 0 (0) 0 (0)
) 0 (0) 0 (0)
) 1 (1.9) 0 (0)
.9) 0 (0) 0 (0)
) 1 (1.9) 0 (0)
Table 3 Incidence of diarrhea after first- and second-line weekly irinotecan and capecitabine
Total Grade I Grade II Grade III Grade IV
Number (%) Number (%) Number (%) Number (%)
First-line treatment 30 (57.7) 10 (33.3) 3 (10) 2 (6.7) 0 (0)
Second-line treatment 22 (42.3) 6 (27.3) 2 (9.1) 1 (4.5) 1 (4.5)
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penia. After symptomatic therapy and prophylactic anti-
biotic treatment, all patients recovered. The incidence of
mild to moderate anemia was 38.5%. One patient discon-
tinued treatment because of grade 3 anemia complicated
by grade 3 fatigue after 5 cycles of wXELIRI, and one
patient had the capecitabine dose reduced due to the
grade 3 hand-foot syndrome after 16 cycles. Table 4
shows the adverse reactions.
Efficacy
After a median follow-up of 13.9 months (range, 1-24
months), 25 of 30 patients (83.3%) treated with wXELIRI
in the first-line setting experienced disease progression,
and 16 patients (53.3%) died (Table 4). The median OS
was 16.3 months (95% confidence interval [CI]: 10.47-
22.13 months) and the median progression-free sur-
vival (PFS) was 8.5 months (95% CI: 6.22-10.78 months)
(Figure 1). Ten patients experienced partial response
(PR) and 11 patients had stable disease (SD), whereas
no complete response (CR) was observed and 3 patients
did not have response evaluation due to withdrawal of
consent after two cycles. The objective response rate
(ORR) was 37% (10/27 patients) and the disease controlTable 4 Analysis of efficacy of weekly irinotecan and capecita




Median OS (months) 16.3
Progression-free survival
Progression events 25 (83.3)








Median number of cycles (range) 12 (1–50)
Median treatment period (months) 3.7
CR: complete response; ORR: overall response rate; OS: overall survival; PD: progressiverate (DCR) was 77.7% (21/27 patients). Secondary R0
metastasectomy was performed in 2 patients after 6 cycles.
In patients pretreated with FOLFOX or XELOX (n = 22),
the median PFS was 5.0 months (95% CI: 1.74-8.26 months)
and the median OS was 10.7 months (95% CI: 5.80-
15.60 months), with a median follow-up period of
13.8 months (range, 1-17 months) (Figure 2). Among
the 21 evaluable patients in the second-line setting,
three (14.3%) achieved PR, and 13 (61.9%) had stable
disease, whereas five (23.8%) had disease progression at
the first efficacy evaluation. One patient withdrew from
the study due to personal reasons after one cycle.
Discussion
This study demonstrated that patients with colorectal
cancer experienced a relatively low incidence of severe
diarrhea with the wXELIRI regimen as first- or second-
line treatment. The incidence of grade 3 and grade 4
diarrhea was 5.8% and 1.9%, respectively. Among the 30
patients who received the study treatment in the first-
line setting, the rate of grade 3 diarrhea was only 6.7%
and no grade 4 diarrhea was observed. This was much
lower than that observed with the 3-week or 2-week
XELIRI [8,10,11,15] and FOLFIRI [12,13] regimens. Inbine as first- or second line treatment
0) Second-line treatment (n = 22)













disease; PFS: progression-free survival; PR: partial response; SD: stable disease.
Figure 1 Overall survival and progression-free survival in the first-line setting. (a) progression-free survival; (b) overall survival.
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nistration of capecitabine was introduced to ensure the
absence of a completely drug-free interval during treat-
ment, while maintaining a reasonable dose intensity, and
a rate of grade 3 diarrhea of 8.1% was obtained. We have
also demonstrated a similar low incidence of severe diar-
rhea in this series when using the same dosing schedule
of capecitabine and dividing the dose of irinotecan from
the FOLFIRI regimen into once weekly administration.
In the literature, the median time for delayed diarrhea
caused by irinotecan was 6-14 days after administration
[18,19]. Diarrhea may be aggravated in the second week
when using the traditional regimen of capecitabine from
days 1 to 14 every 21 days, which may result in discontinu-
ation of the oral fluoropyrimidine causing under-dosage.
Our results indicate that weekly use of capecitabine isFigure 2 Overall survival and progression-free survival in the second-feasible and tolerable with less drug interruption when
combined with irinotecan.
We analyzed the efficacy and survival data according to
the treatment setting. Survival in this study was similar to
that in previous studies in patients undergoing first-line
treatment with irinotecan and capecitabine (Table 5).
About 10% of the patients in our study accepted tar-
geted therapy as subsequent treatment. The median OS
for first-line treatment was comparable with the published
data for patients undergoing chemotherapy [20-23]. In the
second-line setting, wXELIRI showed promising efficacy.
Among 22 patients who had failed prior oxaliplatin, the
ORR was 14.3% and the median PFS was 5.0 months,
which were significantly superior to the ORR of 4% and
PFS of 2.5 months with FOLFIRI after failure of FOLFOX
in the GERGOR study [17], and the median OS exceededline setting. (a) progression-free survival; (b) overall survival.
Table 5 Summary of clinical trials of capecitabine and irinotecan in the first-line setting








Bajetta, et al [9] 2004 CAPIRI vs XELIRI 140 CAPIRI 44 CAPIRI 7.6 — CAPIRI 17
XELIRI 47 XELIRI 8.3 XELIRI 36
Borner, et al [8] 2005 CAPIRI vs XELIRI 75 CAPIRI 34 CAPIRI 6.9 CAPIRI 17.4 CAPIRI 34
XELIRI 35 XELIRI 9.2 XELIRI 24.7 XELIRI 19
Cartwright, et al [10] 2005 XELIRI 49 45 6.2 13.4 20
Patt, et al [11] 2007 XELIRI 52 46 TTP 7.1 15.6 20
Rea, et al [24] 2005 XELIRI 57 42 TTP 8.3 — 9
Garcia-Alfonso, et al [15] 2009 XELIRI (every 2 weeks) 53 40 TTP 8.4 19.3 15.9
Choi, et al [16] 2008 XELIRI (every 2 weeks) 43 51 TTP 10.1 15.4 8.1
CAPIRI: capecitabine and irinotecan; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; TTP: time to progression; XELIRI: irinotecan
and capecitabine.
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patients, it would be interesting to ascertain the survival
data for second-line treatment of colorectal cancer in a
greater number of patients.
The low rate of severe diarrhea enabled a greater in-
tensity of chemotherapy to be achieved, thus ensuring
improved efficacy; a treatment delay of only 4.7% was
observed in this study. Patients experienced more grade
3/4 neutrophilia than in the MAC-6 study [16], but
hematological suppression was easily controlled with
granulocyte colony-stimulating factor support.
It should be admitted that the doses of the weekly
regimen of irinotecan and capecitabine in our study
were not established through a formal phase I study.
However, the tolerable dose for weely-used irinotecan
was evaluated in the previous phase I trial [25], of which
irinotecan with a dose of 100 mg/m2 was given on days
1 and 8, and capecitabine with 2000 mg/m2 on days
1-14 of a 3-week cycle was recommended. In our study,
the dose of irinotecan was chosed based on that in the
FOLFIRI regimen with 180 mg/m2 for 2 weeks [17],
equal to 90 mg/m2 weekly. Although the planned dose
intensities of irinotecan and capecitabine with wXELIRI
were higher than those with the biweekly [15] or every
three weeks [10,11] irinotecan/capecitabine regimen,
the rate of diarrhea decreased while the survival data was
similar, suggesting the feasibility of weekly used regimen.
Additional use of targeted therapy based on irinotecan
and capecitabine is a new direction [20,26-28]. Recent
study data indicated that the 3-week XELIRI regimen
combined with bevacizumab had comparable efficacy to
FOLFIRI combined with bevacizumab, with incidences
of grade 3/4 diarrhea and agranulocytosis of 19% and
13%, respectively [20]. The XELIRI plus cetuximab
regimen also achieved good efficacy with an OS of
more than 20 months [28], but poor tolerance was aconcern as 32% of patients required dose reduction
[29]. Whether the wXELIRI regimen could become an
alternative to combination therapy with targeted drugs
needs further investigation.
Conclusions
The weekly irinotecan and capecitabine combination is
associated with a low incidence of severe diarrhea and
has an acceptable toxicity profile. wXELIRI could be an
alternative regimen for patients with metastatic colorectal
cancer, especially in the second-line setting. Further ran-
domized controlled studies are needed to evaluate the effi-
cacy and safety of this regimen in a larger sample size.
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